| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $94.8M | +55.6% |
| SG&A Expense | $30.3M | +37.0% |
| Operating Income | -$125.1M | -50.6% |
| Income Tax | $0 | — |
| Net Income | -$111.5M | -42.4% |
| EPS (Basic) | -$2.86 | +24.3% |
| EPS (Diluted) | -$2.86 | +24.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $52.6M | -7.3% |
| Short-term Investments | $437.9M | +76.2% |
| Current Assets | $498.6M | +60.9% |
| Total Assets | $512.4M | +62.7% |
| Current Liabilities | $19.0M | +117.3% |
| Total Liabilities | $27.8M | +192.2% |
| Stockholders' Equity | $484.7M | +58.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$87.5M | -34.9% |
| Capital Expenditures | $616K | -74.4% |
| Investing Cash Flow | -$187.5M | -10.2% |
| Financing Cash Flow | $270.8M | +22.2% |
| Free Cash Flow | -$88.1M | -31.0% |